Background: The aim of this study was to examine clinical/pathological characteristics, prognosis and tendency to metastasis of mixed germ cell tumours (MGCTs) that contain a seminoma component. Methods: A total of 111 MGCT cases between 2008 and 2018 were retrospectively enrolled. The patients were divided into 2 groups according to the absence (group 1) or presence (group 2) of seminoma component in MGCTs. Patients’ age, complaints at admission to our clinic, primary tumour localization, primary tumour size, preoperative testicular tumour markers, MGCT histopathological components and percentages, lymphovascular invasion, pathological tumour stage, postoperative testicular tumour markers, presence of lymph node involvement in abdominal tomography, lung metastasis based on thorax tomography, clinical tumour stage, adjunctive therapies performed, state of recurrence and survival were compared in 2 groups. Results: The mean age of the patients was 24.51 ± 4.79 years. The mean age, initial complaint rates, primary tumour size, postoperative testicular tumour markers, presence of lymphovascular invasion, presence of lymph node involvement and lung metastasis were found to be higher in group 2 than in group 1, although these differences were not statistically significant. Especially, it was found that a seminoma component rate of 30% and higher had a higher tendency for a poor prognosis. Conclusion: Although the word “seminoma” may be initially interpreted as an indication of good prognosis, a seminoma component in MGCTs is actually not a good prognostic factor. MGCTs that contain a seminoma component (especially 30% and higher) can have a higher tendency for occult metastatic disease.

1.
Gurney
JK
,
Florio
AA
,
Znaor
A
,
Ferlay
J
,
Laversanne
M
,
Sarfati
D
, et al.
.
International Trends in the Incidence of Testicular Cancer: Lessons from 35 Years and 41 Countries
.
Eur Urol
.
2019
Nov
;
76
(
5
):
615
23
.
[PubMed]
0302-2838
2.
Ivan Damjanov
OH
.
The effects of chemotherapy on metastatic testicular germ cell tumors
.
Open Pathol J
.
2009
;
3
(
2
):
45
52
. 1874-3757
3.
Ulbright
TM
.
Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues
.
Mod Pathol
.
2005
Feb
;
18
(
S2
Suppl 2
):
S61
79
.
[PubMed]
0893-3952
4.
Bahrami
A
,
Ro
JY
,
Ayala
AG
.
An overview of testicular germ cell tumors
.
Arch Pathol Lab Med
.
2007
Aug
;
131
(
8
):
1267
80
.
[PubMed]
1543-2165
5.
Williamson
SR
,
Delahunt
B
,
Magi-Galluzzi
C
,
Algaba
F
,
Egevad
L
,
Ulbright
TM
, et al.;
Members of the ISUP Testicular Tumour Panel
.
The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel
.
Histopathology
.
2017
Feb
;
70
(
3
):
335
46
.
[PubMed]
0309-0167
6.
Albers
P
,
Göll
A
,
Bierhoff
E
,
Schoeneich
G
,
Müller
SC
.
Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors
.
Urology
.
1999
Oct
;
54
(
4
):
714
8
.
[PubMed]
0090-4295
7.
Rajpert-De Meyts
E
.
Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects
.
Hum Reprod Update
.
2006
May-Jun
;
12
(
3
):
303
23
.
[PubMed]
1355-4786
8.
M.P.
Laguna
(Chair) PA, W. Albrecht, F. Algaba, et al. Testicular Cancer. EAU Guidelines on Testicular Cancer 2019.
2019
.
9.
Miyai
K
,
Ito
K
,
Nakanishi
K
,
Tsuda
H
.
Seminoma component of mixed testicular germ cell tumor shows a higher incidence of loss of heterozygosity than pure-type seminoma
.
Hum Pathol
.
2019
Feb
;
84
:
71
80
.
[PubMed]
0046-8177
10.
Moch
H
,
Cubilla
AL
,
Humphrey
PA
,
Reuter
VE
,
Ulbright
TM
.
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
.
Eur Urol
.
2016
Jul
;
70
(
1
):
93
105
.
[PubMed]
0302-2838
11.
Lobo
J
,
Costa
AL
,
Vilela-Salgueiro
B
,
Rodrigues
Â
,
Guimarães
R
,
Cantante
M
, et al.
.
Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists
.
Hum Pathol
.
2018
Dec
;
82
:
113
24
.
[PubMed]
0046-8177
12.
Kollmannsberger
C
,
Tandstad
T
,
Bedard
PL
,
Cohn-Cedermark
G
,
Chung
PW
,
Jewett
MA
, et al.
.
Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance
.
J Clin Oncol
.
2015
Jan
;
33
(
1
):
51
7
.
[PubMed]
0732-183X
13.
Leão
R
,
Ahmad
AE
,
Hamilton
RJ
.
Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer
.
Clin Genitourin Cancer
.
2019
Feb
;
17
(
1
):
e176
83
.
[PubMed]
1558-7673
14.
Klepp
O
,
Flodgren
P
,
Maartman-Moe
H
,
Lindholm
CE
,
Unsgaard
B
,
Teigum
H
, et al.
.
Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA)
.
Ann Oncol
.
1990
Jul
;
1
(
4
):
281
8
.
[PubMed]
0923-7534
15.
Carver
BS
,
Serio
AM
,
Bajorin
D
,
Motzer
RJ
,
Stasi
J
,
Bosl
GJ
, et al.
.
Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors
.
J Clin Oncol
.
2007
Dec
;
25
(
35
):
5603
8
.
[PubMed]
0732-183X
16.
Mead
GM
,
Stenning
SP
.
The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours
.
Clin Oncol (R Coll Radiol)
.
1997
;
9
(
4
):
207
9
.
[PubMed]
0936-6555
You do not currently have access to this content.